The new HIT_TB project is another Foundation and the National Institute of Allergy and Infectious Diseases, along with Pfizer Inc., and academic institutions in the United Kingdom and South Africa. Its focus is on combating tuberculosis, which infects one-third of the world’s population.

This project will support high-throughput screening on whole Mycobacterium tuberculosis bacteria using chemical library of diverse, high-quality molecules. The goal is to identify a series of well-characterized small molecules with defined, tractable bacterial targets, which have the potential for development into better drugs against tuberculosis.